Trial | NCT03329443  Report issue

Official Title

The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    490
an interventional study to measure the possible effects of spironolactone ( an aldosterone antagonist) on the incidence of acute kidney injury after coronary angiography
Study Started
Sep 01
2017
Primary Completion
Sep 01
2018
Study Completion
Sep 04
2018
Last Update
Sep 10
2018

Drug Spironolactone

each patient will receive 200 mg of spironolactone as per his/her angiography premedications

  • Other names: Active group

Drug Placebo Oral Tablet

Each patient will receive a placebo tablet as per his/her angiography premedications

  • Other names: Control group

placebo Placebo Comparator

Spironolactone Active Comparator

Criteria 

Inclusion Criteria:

patients admitted to angiography unit
over 18
informed consent

Exclusion Criteria:

acute renal failure before 7 days
spironolactone contraindications
hyperkalemia (S.K. >5.5 mEq/L)
documented tumor
actively taking NSAIDs, Ciclosporin, Cisplatin,
No Results Posted